Taken together, non-nuclear signaling plays a major role in estrogen-induced protection against vascular injury, and compounds that activate non-nuclear signaling might provide a vascular benefit as non-nuclear selective ER modulators without increasing the risk of uterine or breast cancer. This evidence concerns the gene ESR1 and breast cancer.